Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (2478)	9/7/2010 3:30:55 PM
From: tuck	1 Recommendation Read Replies (2) of 3027

I have to agree with Dew here: the FDA must have had some way around this in mind to accept an ANDA, as this in vivo/in vitro assay issue was known before the FDA accepted it. Anyhow, so the motion for summary judgement is denied, meaning the case will probably go to trial. Our friend the Bernstein analyst figures this means 2012 at earliest for a generic Copaxone to get through, and that seems reasonable. Probably the reason Momenta rebounded today, though, was the same analyst's assertion that the Copaxone patents are vulnerable on the prior art/obviousness issue, i.e. that they are too much based on the expired 350 patent. This guy Ronny Gal seems to be the axe in the name for now. I managed to pick up some cheap options due to a lowball limit order I had in, and now have a nearly full position again. Feel free to partner something now, Momenta. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next